Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1986 2
1987 1
1988 3
1989 7
1990 6
1991 8
1992 3
1993 4
1994 11
1995 10
1996 9
1997 5
1998 8
1999 7
2000 4
2001 10
2002 17
2003 14
2004 12
2005 17
2006 17
2007 13
2008 16
2009 13
2010 19
2011 20
2012 12
2013 19
2014 20
2015 11
2016 13
2017 10
2018 11
2019 12
2020 9
2021 15
2022 12
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Results by year

Filters applied: . Clear all
Page 1
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Abou-El-Enein M, et al. Among authors: heslop he. Blood Cancer Discov. 2021 Sep;2(5):408-422. doi: 10.1158/2643-3230.BCD-21-0084. Epub 2021 Aug 3. Blood Cancer Discov. 2021. PMID: 34568831 Free PMC article. Review.
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Ramos CA, et al. Among authors: heslop he. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23. J Clin Oncol. 2020. PMID: 32701411 Free PMC article. Clinical Trial.
Engineered off-the-shelf therapeutic T cells resist host immune rejection.
Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. Mo F, et al. Among authors: heslop he. Nat Biotechnol. 2021 Jan;39(1):56-63. doi: 10.1038/s41587-020-0601-5. Epub 2020 Jul 13. Nat Biotechnol. 2021. PMID: 32661440 Free PMC article.
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.
Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA. Levine BL, et al. Among authors: heslop he. Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w. Nat Med. 2024. PMID: 38195751 No abstract available.
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M. Watanabe N, et al. Among authors: heslop he. Mol Ther. 2023 Jan 4;31(1):24-34. doi: 10.1016/j.ymthe.2022.09.003. Epub 2022 Sep 9. Mol Ther. 2023. PMID: 36086817 Free PMC article.
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
Pfeiffer T, Tzannou I, Wu M, Ramos C, Sasa G, Martinez C, Lulla P, Krance RA, Scherer L, Ruderfer D, Naik S, Bocchini C, Fraser IP, Patel B, Ward D, Wang T, Heslop HE, Leen AM, Omer B. Pfeiffer T, et al. Among authors: heslop he. Clin Cancer Res. 2023 Jan 17;29(2):324-330. doi: 10.1158/1078-0432.CCR-22-2415. Clin Cancer Res. 2023. PMID: 36628536 Free PMC article. Clinical Trial.
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Luznik L, et al. Among authors: heslop he. J Clin Oncol. 2022 Feb 1;40(4):356-368. doi: 10.1200/JCO.21.02293. Epub 2021 Dec 2. J Clin Oncol. 2022. PMID: 34855460 Free PMC article. Clinical Trial.
Inducible apoptosis as a safety switch for adoptive cell therapy.
Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Di Stasi A, et al. Among authors: heslop he. N Engl J Med. 2011 Nov 3;365(18):1673-83. doi: 10.1056/NEJMoa1106152. N Engl J Med. 2011. PMID: 22047558 Free PMC article. Clinical Trial.
Tumor-intrinsic causes of CAR-T failure.
Heslop HE. Heslop HE. Blood. 2022 Aug 4;140(5):414-415. doi: 10.1182/blood.2022016851. Blood. 2022. PMID: 35925642 Free PMC article. No abstract available.
Antiviral T-cell therapy.
Leen AM, Heslop HE, Brenner MK. Leen AM, et al. Among authors: heslop he. Immunol Rev. 2014 Mar;258(1):12-29. doi: 10.1111/imr.12138. Immunol Rev. 2014. PMID: 24517423 Free PMC article. Review.
387 results